K. Thomas

Evaluation of short-course direct-acting antivirals and ezetimibe to prevent HCV infection in recipients of organs from HCV-infected donors: A single-centre, open-label study

H. Dahari, Deepali Kumar, S. Kim, 2020 .

A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.

J. Schellens, A. Le Cesne, M. D. de Jonge, 2017, European journal of cancer.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens, M. D. de Jonge, M. Langenberg, 2018, British Journal of Cancer.

A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours

J. Schellens, M. D. de Jonge, M. Langenberg, 2018, British Journal of Cancer.